PV Bulletin
PvBulletin
Home /Regulators/Covidien MonaTherm General Purpose Temperature Probe Recall (Class 2)
RegulatorsFDAUSA

Covidien MonaTherm General Purpose Temperature Probe Recall (Class 2)

Covidien (Medtronic) recalls specific lots of MonaTherm probes due to potential incorrect temperature readings or quality defects.

PV Impact Brief

Urgency: HighConfidence: high
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Action needed

Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.

Owner

Regulatory Intelligence Lead

Review cadence

single event

Regulatory action details

Action type
Class 2 Device Recall
Publication date
June 01, 2026
Safety issue
Corrosion of the internal metallic spring within the sprayer component due to material incompatibility with the solution, potentially resulting in visible discoloration and trace levels of metallic elements in the solution.

Affected products

  • PhaseOne Antimicrobial Solution
    Oculus Technologies of Mexico, S.A. de C.V.
    25G263

PV internal implications

Do not use and discard any sprayers included with PhaseOne 50 ml bottles. Product units not assembled with sprayer may be used by pouring solution directly from bottle.

View regulator source

Evidence and confidence

Confidence: highSource updated: May 29, 2026

Full briefing

What changed

FDA classified the Covidien MonaTherm probe recall as Class 2 and instructed users to quarantine and return unused products.

Why it matters

Incorrect temperature readings could lead to misdiagnosis or inappropriate patient management, posing serious safety risks.

Practical implication

Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.

Related updates for your role

RegulatorsMedicines and Healthcare products Regulatory Agency (MHRA)United Kingdom

MHRA Largest Seizure of Unlicensed Weight Loss Medicines

Regulatory action
Enforcement Action / Public Safety Alert
Unlicensed weight loss medicines · Illicit manufacturing operation (unnamed)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief
RegulatorsFDAUnited States

FDA Public Notification: Tawon Liar Contains Hidden Drug Ingredients

Regulatory action
Public Notification
Tawon Liar
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: HighConfidence: high
Read impact brief
AI/GxPFdaUnited Kingdom

MHRA updates SaMD/AIaMD guidance, highlighting PCCP and transparency principles

Relevant for
Signal Management LeadRegulatory Intelligence LeadMedical Device Vigilance LeadPV Quality Lead+2 more
Action needed

Ask the safety/device vigilance and PV CSV leads to: (1) confirm whether any marketed/fielded SaMD/AIaMD uses adaptive ML or planned updates that would fit a PCCP-like approach; (2) review current change-control SOPs and technical documentation to ensure change governance and transparency artifacts are captured and retrievable; (3) verify post-market/vigilance processes explicitly account for algorithm updates (e.g., monitoring after updates, escalation criteria).

Process impact
Risk ManagementDevice VigilanceInspection Readiness
SOP impact

5 SOPs may need review

Urgency: HighConfidence: medium
Read impact brief
RegulatorsEuropean Medicines Agency (EMA)European Union

EMA ETF recommends updating COVID-19 vaccines to target XFG variant for 2026/2027 campaign

Regulatory action
Regulatory Recommendation / Public Health Communication
COVID-19 vaccines · Marketing authorisation holders (various)
Relevant for
Regulatory Intelligence LeadSignal Management Lead
Action needed

Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

Process impact
Signal ManagementLabeling
SOP impact

2 SOPs may need review

Urgency: MonitorConfidence: high
Read impact brief
Covidien MonaTherm General Purpose Temperature Probe Recall (Class 2) | PV Bulletin